News
-
Novoteris has announced that Health Canada has okayed a planned Phase 2a clinical trial of the company’s Thiolanox inhaled nitric oxide gas for the treatment of non-tuberculous mycobacteria (NTM) lung infections. The study will enroll… Read more . . .
-
Capsugel has announced the addition of an Xcelodose 600S filling machine for micro-dosing of powders into capsules at its facility in Edinburgh, Scotland. Capsugel was acquired by Lonza earlier this year. The Edinburgh facility’s Site… Read more . . .
-
Cyrano Therapeutics has announced a partnership agreement with Chinese CRO Shanghai Newsummit Biopharma (Newsummit) for development of Cyrano’s intranasal theophylline for the treatment of taste and smell disorders in China. Newsummit will provide development services… Read more . . .
-
Impel NeuroPharma has announced the initiation of a Phase 1 trial of INP104 intranasal dihydroergotamine (DHE), which the company is developing for the treatment of acute migraine headache. The bioavailability study, which is taking place… Read more . . .
-
Optinose has announced the appointments of Ricci Whitlow as Vice President of Technical Operations, Harry Sacks as VP of Medical Affairs and Corporate Medical Officer, John Peterkins as VP of Market Access, David Fabbri as… Read more . . .
-
Savara has announced that it will develop its Molgradex inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and plans to initiate a Phase 2a trial for that indication in… Read more . . .
-
Intranasal etripamil developer Milestone Pharmaceuticals has announced the appointment of Lorenz Muller as Chief Commercial Officer. Muller was most recently VP, Marketing at Exact Sciences Corporation and has previously held positions at Daiichi Sankyo, CV… Read more . . .
-
The FDA has approved an updated nebulizer for use with United Therapeutics’ Tyvaso treprostinil inhalation solution for the treatment of pulmonary arterial hypertension, the company said. The new TD-300/A device will be launched next year.… Read more . . .
-
Evoke Pharma says that a comparative exposure PK study has shown that 2 out of 3 doses of its Gimoti metoclopramide nasal spray demonstrated bioequivalence to oral metoclopramide and, based on those results, the company… Read more . . .
-
Submit scientific poster abstracts by January 8, 2018 using the online submission form. Abstracts should be 3-5 pages double spaced and may address any topic related to pulmonary or nasal drug delivery. Top abstracts will… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA